Physician profile
Laura E Sneed
NPI 1629238167
$5,492.79
in general payments reported to CMS, 2019-2025
32 companies · $1,378 in 2025
The $1,378 reported for 2025 was more than what 86% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $755 · 2022: $912 · 2023: $921 · 2024: $1,527 · 2025: $1,378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,807 · Education: $18.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,806.85 |
| Education | $18.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,195.99 | 2021-2025 | Fintepla, Briviact, Nayzilam |
| Neurelis, INC. | $711.56 | 2021-2025 | Valtoco |
| Sk Life Science, INC. | $641.15 | 2021-2025 | Xcopri |
| Corium, LLC | $409.14 | 2023-2025 | Azstarys |
| Jazz Pharmaceuticals INC. | $304.77 | 2022-2024 | |
| Abbvie INC. | $285.39 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $229.83 | 2023-2025 | Daybue |
| Aquestive Therapeutics, INC. | $175.75 | 2021-2025 | |
| Pfizer INC. | $172.24 | 2024-2025 | |
| Supernus Pharmaceuticals, INC. | $169.01 | 2022-2025 | Qelbree |
| Immedica Pharma US, INC. | $162.17 | 2023-2024 | |
| Sumitomo Pharma America, INC. | $160.78 | 2023 | Aptiom |
| Greenwich Biosciences, INC. | $120.63 | 2021 | |
| Lilly USA, LLC | $108.29 | 2021-2023 | Reyvow, Emgality |
| Aucta Pharmaceuticals, INC. | $80.22 | 2025 | Motpoly Xr |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $58.71 | 2023-2025 | Austedo Xr, Ajovy |
| Cranial Technologies, INC | $53.71 | 2022-2025 | Doc Band |
| Eisai INC. | $53.10 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $47.10 | 2023-2024 | Nuedexta |
| Collegium Pharmaceutical, INC. | $39.12 | 2025 | Jornay Pm |
| Travere Therapeutics, INC. | $35.69 | 2021 | |
| Xeris Pharmaceuticals, INC. | $33.65 | 2022 | |
| Biomarin Pharmaceutical INC. | $33.55 | 2024 | Brineura |
| Adlon Therapeutics L.P. | $30.21 | 2021 | |
| Intrabio INC | $25.88 | 2025 | Aqneursa |
| Biogen, INC. | $25.16 | 2024 | Spinraza |
| Sarepta Therapeutics, INC. | $23.34 | 2022 | |
| Livanova USA, INC. | $23.20 | 2022 | |
| Argenx US, INC. | $22.60 | 2025 | Vyvgart Hytrulo |
| Biohaven Pharmaceuticals, INC. | $20.62 | 2021 | |
| Azurity Pharmaceuticals, INC. | $20.29 | 2024 | Zonisade |
| Tris Pharma INC | $19.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Sneed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.